New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
08:39 EDTXONIntrexon enters exclusive channel collaboration with Amneal
Amneal Pharmaceuticals and Intrexon Corporation announced the formation of an Exclusive Channel Collaboration, or ECC, to develop an improved production process for a complex active pharmaceutical ingredient. The companies will continue to explore other similar opportunities for collaboration in the future, they stated.
News For XON From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
19:31 EDTXONOn The Fly: After Hours Movers
UP AFTER EARNINGS: Progress Software (PRGS), up 1%. ALSO HIGHER: Repros Therapeutics (RPRX), up 21.9% after announcing acceptance for filing of NDA its enclomiphene citrate product... TCP International (TCPI), up 13.7% after announcing that product validation is proceeding as expected... Intrexon (XON), up 2.4% after signing a CRADA with NCI for RTS platform. DOWN AFTER EARNINGS: Sigma Designs (SIGM), down 2.8%... Micron Technology (MU), down 1.7%. ALSO LOWER: Conatus Pharmaceuticals (CNAT), down 4.4% after filing to sell common stock... TrueCar (TRUE), down 1.8% after being initiated with a Sell at B. Riley... ZIOPHARM Oncology (ZIOP), down 1.8% after filing to sell 11.72M shares of common stock for holders.
16:19 EDTXONIntrexon signs CRADA with NCI for RTS platform
Intrexon has signed a Cooperative Research and Development Agreement, or CRADA, with the National Cancer Institute, or NCI, part of the National Institutes of Health, for the development of adoptive T cell therapies utilizing the RheoSwitch Therapeutic System, or RTS, platform for the treatment of solid tumor malignancies. The principal goal of the CRADA is to develop and evaluate improved adoptive cell transfer-based immunotherapies, or ACT, using NCI proprietary methods for the identification of autologous peripheral blood lymphocytes, or PBL, possessing naturally occurring anti-tumor activity combined with Intrexon's RTS gene switch for introducing spatially and temporally controlled interleukin-12 expression.
March 30, 2015
10:10 EDTXONMizuho says scale, speed of Intrexon-Ziopharm deal a positive
Subscribe for More Information
09:27 EDTXONOn The Fly: Pre-market Movers
Subscribe for More Information
08:12 EDTXONIntrexon, Merck Serono announce agreement for CAR-T development
Subscribe for More Information
08:12 EDTXONZiopharm-Intrexon announce collaboration with Merck KGaA for CAR-T products
ZIOPHARM Oncology (ZIOP) and Intrexon (XON) announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell, or CAR-T, products with Merck Serono, the biopharmaceutical division of Merck KGaA (MKGAY). Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with ZIOPHARM. Under the collaboration Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Through its agreement with Intrexon, ZIOPHARM will be responsible for any additional research and development expenditures. Once these candidates reach investigational new drug stage, the programs will be transferred to Merck Serono for clinical development and commercialization. ZIOPHARM and Intrexon will also independently conduct research and development on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. ZIOPHARM's other oncology programs will continue through its Exclusive Channel Collaboration with Intrexon.
March 27, 2015
12:33 EDTXONLegg Mason's Miller says Intrexon, Amazon two of largest positions
12:28 EDTXONIntrexon, Ziopharm mentioned as stock picks by Bill Miller on CNBC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use